Take 1 capsule daily with water, preferably with food, or as directed by a healthcare professional.

Consult a healthcare professional before use if pregnant, breastfeeding, taking medication, or under medical supervision.

For adult use only.

Store in a cool, dry place.
Keep out of reach of children.
Store in a cool, dry place between 5–25°C.
Protect from direct sunlight.

PQQ (Pyrroloquinoline Quinone), NMN (Nicotinamide Mononucleotide).

Pyrroloquinoline quinone (PQQ) Clinical Trials:

- A 12-week trial with 20 mg/day of PQQ improved complex and verbal memory in adults aged 41–65. 

- In younger adults (21–40 years), the same dose enhanced cognitive flexibility and executive speed, suggesting age-dependent cognitive benefits. 

- Additional studies show improvements in prefrontal cortex blood flow, sleep quality, fatigue reduction, and LDL-cholesterol levels. 

Human trials confirming NMN’s efficacy:

- A multicenter, randomized, double-blind, placebo-controlled trial demonstrated that NMN supplementation significantly increased NAD+ levels and improved inner retinal function in glaucoma patients, as measured by photopic negative response (PhNR) parameters. 

- In elderly participants, 250 mg/day of NMN for 8 weeks improved muscle strength and reduced fatigue, indicating functional benefits in age-related decline. 

- NMN has also shown promise in age-related macular degeneration (AMD), where it enhanced ATP production in retinal pigment epithelium (RPE) cells from AMD patients, though responses were highly individualized.

Pyrroloquinoline quinone (PQQ) is a redox-active cofactor with potent antioxidant properties that supports mitochondrial health by stimulating mitochondrial biogenesis, the creation of new mitochondria. It protects against oxidative stress, modulates inflammatory pathways, and enhances cellular energy output. PQQ has been shown to improve markers of cognitive function, interoception, and metabolic health in human trials. The following research supports the above:

Nakano et al. (2009) Demonstrated that oral PQQ supplementation supports mitochondrial biogenesis and improves markers of cellular energy metabolism in humans and animal models.

Harris et al. (2013) Human clinical study showed PQQ supplementation improved fatigue scores, sleep quality, and cognitive function markers in healthy adults.

Nakano et al. (2012) PQQ intake was associated with reduced oxidative stress markers and improved mitochondrial efficiency in human subjects.

Stites et al. (2020) Reported improvements in attention, processing speed, and working memory associated with mitochondrial support nutrients including PQQ.



Nicotinamide mononucleotide (NMN) is a direct precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for energy metabolism, DNA repair, and sirtuin activation (e.g., SIRT1), which are central to longevity pathways. As NAD+ levels decline with age, NMN supplementation aims to restore cellular NAD+ pools, supporting mitochondrial function and genomic stability. The following research supports the above:

Irie et al. (2020) First human clinical trial confirming oral NMN safely increases blood NAD+ levels, supporting cellular metabolism and mitochondrial function.

Yoshino et al. (2021) Randomized controlled trial demonstrated NMN improved muscle insulin sensitivity and metabolic function in prediabetic women.

Nishida et al. (2022) Showed NMN supplementation enhanced aerobic capacity and skeletal muscle function in healthy adults.

Liao et al. (2021) Demonstrated improvements in vascular function and reduced arterial stiffness associated with NAD+ restoration via NMN supplementation.